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Abstract
Objective—The association between cholesterol and endothelial dysfunction remains
controversial. We tested the hypothesis that lipoprotein subclasses are associated with coronary
endothelial dysfunction.
Methods and Results—Coronary endothelial function was assessed in 490 patients between
November 1993 and February 2007. Fasting lipids and nuclear magnetic resonance (NMR)
lipoprotein particle subclasses were measured. There were 325 females and 165 males with a mean
age of 49.8±11.6 years. Coronary endothelial dysfunction (epicardial constriction >20% or increase
in coronary blood flow <50% in response to intracoronary acetylcholine) was diagnosed in 273
patients, the majority of whom (64.5%) had microvascular dysfunction. Total cholesterol and LDL-
C (low density lipoprotein cholesterol) were not associated with endothelial dysfunction. One-way
analysis and multivariate methods adjusting for age, gender, diabetes, hypertension and lipid-
lowering agent use were used to determine the correlation between lipoprotein subclasses and
coronary endothelial dysfunction. Epicardial endothelial dysfunction was significantly correlated
with total (p = 0.03) and small LDLp (LDL particles) (p<0.01) and inversely correlated with total
and large HDLp (high density lipoprotein particles) (p <0.01).
Conclusions—Epicardial, but not microvascular, coronary endothelial dysfunction was associated
directly with LDL particles and inversely with HDL particles, suggesting location-dependent impact
of lipoprotein particles on the coronary circulation.
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INTRODUCTION
The coronary endothelium is an active site of continuous vascular injury and repair. Endothelial
integrity reflects the homeostatic balance between oxidative endothelial injury and endogenous
reparatory processes1, 2. Endothelial dysfunction is an early central phase in the evolution of
atherosclerosis and independently predicts future cardiovascular events2. Although endothelial
function assessment has not yet gained routine use in clinical practice, there is a substantial
body of evidence supporting its predictive value for cardiovascular events. Multivariate
analysis of 10 studies with follow-up as long as 92 months, showed that endothelial dysfunction
is associated with a 3- to 5-fold increase in events compared to normal patients2.
Coronary endothelial function can be assessed by the intracoronary administration of the
endothelium dependent vasodilator acetylcholine3. Lack of coronary vasodilation and/or
increase in coronary blood flow signifies epicardial and microvascular endothelial dysfunction,
respectively. Both are regarded as markers of early atherosclerosis. Although total cholesterol,
elevated LDL-C and low HDL-C are well established risk factors for CVD (cardiovascular
disease), a consistent association with endothelial dysfunction has not been consistently
demonstrated.
Lipoprotein lipid concentrations are not equivalent to lipoprotein particle concentrations.
Patients with identical lipoprotein concentrations may have very different lipid particle
concentrations and subsequently different cardiovascular risks. Lipoprotein lipid measurement
therefore may not differentiate risk in patients as it does not directly measure the proportion
of atherogenic subclasses and their attendant cardiovascular risk4, 5. Normocholesterolemic
patients with high levels of small dense LDLp have increased CVD4, 6 while higher
concentrations of large HDLp appear to have a protective effect7. Associations have been found
between small LDLp and coronary artery calcification8, 9, the metabolic syndrome10, 11 and
the degree of angiographic coronary stenosis12. Even with adjustment for LDL-C, LDLp are
still strongly associated with CVD outcomes and incident coronary heart disease6, 13.
NMR analysis was developed in the early 1990’s and is a more feasible technique that correlates
well with earlier centrifugation14. It allows for quantitation of both lipoprotein particle
concentration and size unlike electrophoretic methods which determine only their size. The
purpose of this study is to test the hypothesis that lipoprotein particles are associated with
coronary endothelial dysfunction.
METHODS
This study was approved by the Institutional Review Board. Informed consent was obtained
from all participants. The study group was comprised of 490 patients referred for invasive
endothelial function testing for evaluation of chest pain. Patients withheld all potentially
vasoactive medications for at least 24 hours prior to. Fasting blood samples were obtained on
the same day of the angiogram and used for NMR analysis.
Study Protocol
Assessment of Coronary Endothelial Function—The methodology for coronary
endothelial function analysis has been described previously2, 3, 15. Diagnostic coronary
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angiography was performed and patients with significant obstructive coronary disease
(stenoses >30%) were excluded. A Doppler guide wire (FloWire®, Volcano Corp, Rancho
Cordova, California) was positioned within a coronary infusion catheter (Ultrafuse®, SciMed
Life Systems, Minneapolis, Minnesota) in the mid left anterior descending artery.
Endothelium-independent microvascular coronary flow reserve was assessed by
administration of intracoronary bolus injections of incremental doses (18–60 μg) of adenosine
until either maximal hyperemia was achieved or the largest dose was given.
Endothelium-dependent vasoreactivity was assessed by intracoronary administration of
acetylcholine selectively infused at increasing concentrations (10−6, 10−5, 10−4 mol/L) for 3
minutes at each concentration. Hemodynamic parameters were measured and angiography was
performed after each infusion of acetylcholine. At the end of the procedure, the change in
coronary artery diameter in response to a 100ug bolus of intracoronary nitroglycerin (Abbott
Laboratories, Abbott Park, Illinois) was assessed.
Epicardial endothelial dysfunction was defined as a decrease in coronary artery diameter >20%
in response to maximum dose of intracoronary acetylcholine and microvascular endothelial
dysfunction as ≤ 50% increase in coronary blood flow (CBF)16. Endothelial dysfunction was
defined as the presence of either epicardial or microvascular dysfunction.
Nuclear Magnetic Resonance Spectroscopy—Fasting blood samples were obtained
from the study subjects prior to diagnostic coronary angiography. Patients had no alcohol for
24 hours before the test. They had no fatty foods in their last evening meal taken before 6PM
the day before the test. Lipoprotein particle concentrations and size were measured in our
laboratory with a 400 MHz NMR analyzer using an automated commercial NMR spectroscopic
assay (NMR LipoProfile®, LipoScience, Inc., Raleigh, NC)14. Concentrations of VLDL and
LDL (including IDL) subclasses in nmol/L units and HDL subclasses in μmol/L units were
obtained from the measured amplitudes of the distinct lipid methyl group NMR signals they
emit.
The estimated diameters of the 9 measured subclasses are as follows: large VLDL (>60 nm),
medium VLDL (35–60 nm), small VLDL (27–35 nm), IDL (23–27 nm), large LDL (21.2–23.0
nm), small LDL (18.0–21.2 nm), large HDL (8.8–13.0 nm), medium HDL (8.2–8.8 nm), and
small HDL (7.3–8.2 nm). Total LDL and HDL particle concentrations are the sum of the IDL,
large LDL, and small LDL subclass concentrations and large, medium, and small HDL subclass
concentrations, respectively. Weighted-average VLDL, LDL, and HDL particle sizes were
calculated by summing the diameter of each subclass multiplied by its relative mass percentage
as estimated by the amplitude of its methyl NMR signal. Inter-assay reproducibility,
determined from replicate analyses of plasma pools, is indicated by the following coefficients
of variation: <0.6% for LDL size, <5% for total LDL and HDL particle concentrations, <6%
for large HDL particle concentration, and <15% for small LDL particle concentration14.
Statistical Analysis
Statistical analysis was performed by a statistician who was blinded to the clinical data.
Continuous variables were presented as mean +/− standard deviation (SD) and dichotomous
variables as frequencies and percentages. Baseline characteristics of patients with and without
endothelial dysfunction were compared using a two-sample t test for continuous variables and
by the Pearson chi-square statistic for categorical variables. Single predictor and multivariable
logistic regression models were used to calculate the effect of individual lipoprotein subclasses
on endothelial function. Adjustments were made for age, gender, hypertension, diabetes
mellitus and statin use in multivariable logistic regression models. Associations with a p value
<0.05 were considered to be statistically significant. Analysis was performed using JMP
(version 7, SAS Institute, Inc., Cary, NC).
Ford et al. Page 3
Atherosclerosis. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
RESULTS
The study population consisted of 490 patients undergoing endothelial function assessment
between November 17, 1993 and February 16, 2007. Table 1 shows the baseline characteristics
of the study population. The mean age was 49.8 years (range 19 to 78 years). There was a
predominance of females (325 females and 165 males) and Caucasians (444 white and 46 non-
whites). The distribution of conventional risk factors was: diabetes mellitus 7.6% (n=37),
hypertension 42% (n= 206), current smoking 12.7% (n= 62) and hyperlipidemia 55.3%
(n=271). Hyperlipidemia was defined as total cholesterol > 200mg/dl, triglycerides >150mg/
dl, LDL-C >100mg/dl or current use of a lipid-lowering agent which was being used by 35.3%
(n=173) of patients. The mean lipid values were: total cholesterol 190 ± 45mg/dl, triglycerides
139 ± 88 mg/dl, HDL-C 53 ±17mg/dl and LDL-C 109 ± 37 mg/dl.
Coronary endothelial dysfunction was diagnosed in 273 patients. There were 251 patients with
microvascular dysfunction, 177 patients with epicardial dysfunction and 156 patients with both.
The test was normal in 179 patients. Results were missing or incomplete in 38 patients. Diabetes
mellitus and body mass index were the only clinical variables associated with endothelial
dysfunction. Univariate analysis showed that coronary endothelial dysfunction was associated
with HDL-C (p=0.02) but not with any other conventional lipid parameter.
We then analyzed the lipid and lipoprotein associations by the type of coronary endothelial
dysfunction (microvascular versus epicardial). Despite lack of significant associations with
conventional lipid levels (Table 1), there were statistically significant positive associations
with total and small LDLp and an inverse correlation with large HDLp (Table 2).
These associations persisted when adjusted for age, gender, hypertension and statin use. When
adjusted for diabetes, small LDLp remained significantly associated with coronary endothelial
dysfunction (r2 = 0.04, p=0.03) and persisted with further adjustment for triglyceride
concentrations (r2 = 0.02, p = 0.03). However, the inverse association with large HDLp was
weakened (r2 = 0.03, p=0.09). When mean LDLp size was included in the model, the
relationship between endothelial dysfunction and small LDLp was reduced (p = 0.16) but the
relationship with diabetes again persisted (p = 0.01) and was independent of statin use (p =
0.19). There was no statistically significant association between any particle and microvascular
dysfunction in either univariate or multivariate analysis. The associations were not affected by
gender. The presence of both epicardial and microvascular dysfunction did not change the
association with LDLp or HDLp.
Hemodynamic data are shown in Table 3. Analysis of coronary epicardial function using the
maximal increase in coronary artery diameter to acetylcholine relative to tertiles of small LDLp
and large HDLp was then performed. With increasing tertiles of small LDLp, there was a
statistically significant, progressive decline in epicardial response to intracoronary
acetylcholine (Figure 1). Conversely, the maximal change in coronary artery diameter
increased with increasing tertiles of large HDLp as shown in Figure 2.
DISCUSSION
This is the first study to report the relationship between early coronary atherosclerosis and
NMR-derived lipoprotein particles in humans. The major findings were: 1) traditional
cholesterol measures (total and LDL-C) are not associated with endothelial dysfunction, 2)
epicardial dysfunction is positively correlated with small LDLp and inversely correlated with
large HDLp, 3) the association of endothelial dysfunction with LDLp is independent of the
presence of conventional risk factors and, 4) there is a differential effect on the epicardial versus
the microvascular circulation.
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Coronary Endothelial Dysfunction and LDL particles
The mean lipid levels in our study cohort would be considered low to intermediate without
particular need for intervention by current guidelines17. Thus, risk assessment based solely on
conventional lipids would have failed to identify those with early coronary atherosclerosis
which was present in over 60% of the study population. However, their risk was discriminated
by LDLp (Figure 1), underscoring a potential biological link and addition of incremental value
to the standard lipid profile.
The lack of the predictive value of total LDL for cardiovascular events was recently
demonstrated in several landmark clinical primary prevention trials18–20 which demonstrated
significantly stronger associations between LDLp and CVD outcomes than with standard
lipids. Epidemiological data suggests that approximately 20–25% of patients have discordance
between LDL-C) and LDLp in the blood21. In the EPIC (European Prospective Investigation
into Cancer and Nutrition)-Norfolk study6, a prospective study of apparently healthy
individuals with moderately elevated LDL-C, LDLp was a better predictor of future
cardiovascular events than LDL-C. In the large community-based Framingham Offspring
cohort4, LDLp were again more sensitive indicators of cardiovascular risk than either LDL-C
or non-HDL-C.
LDLp have also been shown to be superior in several secondary prevention trials12, 21 and in
patients with acute coronary syndromes. For example, in the PROVE-IT TIMI 22 trial22, the
mean LDL-C level (106mg/dl) was similar to that in our patient cohort. Despite a relatively
low mean LDL-C of 62mg/dl in the aggressively treated arm, there remained a continuous
incidence of major cardiovascular events. These observations lead us to speculate, like other
investigators, that total LDL-C may not be most appropriate target for treatment. It is not yet
known to what extent patients in a secondary prevention setting display LDL discordance.
Our study underscores the importance of measuring lipoprotein particles and provides
preliminary evidence that high concentrations of small LDLp should raise the clinician’s
suspicion of the presence of early atherosclerosis. Direct causality between both entities is still
speculative. Growing evidence implicates small LDLp as the key mediator of atherosclerosis
via oxidized LDL23. Small LDLp are more susceptible to oxidation24, 25, impair acetylcholine-
induced vasodilatation, reduce endothelial nitric oxide activity23, 26, increase oxidative
stress27 and are less readily cleared from the circulation26. These studies used gradient gel
electrophoresis for measurement of lipoprotein particles but we anticipate similar results would
be obtained using NMR spectroscopy given the high correlation between both techniques14,
28. Further studies are needed to determine if small LDLp could be a used as a surrogate for
endothelial function assessment.
In the current study, the association between coronary endothelial dysfunction and LDLp was
independent of diabetes mellitus. Similarly, Woodman et al described independent associations
between oxidized and small LDLp size and peripheral endothelial dysfunction in diabetics23.
Cardiovascular risk in diabetic patients with LDL-C <100mg/dl may be underestimated by
their LDL-C values. LDLp are superior to non-HDL cholesterol4 and may also be useful risk
stratification markers in intermediate cardiovascular risk populations. This could facilitate
earlier treatment with agents such as statins and fibrates which decrease LDLp and may even
shift them to larger, more buoyant subtypes29.
Statins and ACE inhibitors were not associated with better endothelial function and did not
affect the correlation with LDLp. Only one-third of patients were on these medications, in
varying doses and for different durations. Differences between the groups would therefore be
difficult to detect. Patients were also relatively young and had minimal atherosclerosis. The
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study personnel were not involved in treatment decisions prior to the patients’ enrollment in
the study.
The correlation between lipoprotein particles and endothelial function was only observed in
the epicardial vasculature; the microvasculature was unaffected. We have previously observed
this microvascular sparing effect in young smokers30. We speculate that since atherosclerotic
plaque formation is a macrovascular phenomenon, correlations would only be seen in the
epicardial coronaries.
Large HDL Particles are Inversely Associated with Coronary Endothelial Dysfunction
Our findings extend previous observations that the protective effect of HDL is strongest with
larger HDLp. We did not find positive correlation between small HDLp and endothelial
dysfunction as reported in other studies31. This may have been because the mean HDL-C level
in our study population was relatively high (53mg/dl). Nevertheless, the reverse correlations
between HDLp and coronary endothelial function support the significance of our findings.
We postulate several potential mechanisms for our observation that large HDLp and not small
HDLp were inversely associated with endothelial dysfunction. Large HDLp may be less
cleared from the systemic circulation and therefore mediate more hepatic recycling of
cholesterol. Conversely, small HDLp may be cleared more from the circulation and deposit
more in arterial walls, with increasing inflammatory consequences, in a similar manner to small
LDLp. In the recent ILLUMINATE trial32, the use of the cholesteryl ester transfer protein
(CETP) inhibitor, torcetrapib, increased HDLp but caused hypertension and increased
cardiovascular complications. More recent studies have shown that these deleterious effects
are a direct effect of the torcetrapib molecule itself and not to elevated HDLp {Vergeer, 2008
#1; Forrest, 2008 #2}. In fact, increasing levels of HDLp with novel CETP inhibitors have not
been associated with these adverse effects and have been shown, as in our current study, to be
associated with improved endothelial function {Hermann, 2009 #140}.
Our study limitations include the lack of generalization of our findings to an asymptomatic
population. The study population was referred and highly selected by exclusion of patients
with significant coronary artery disease. Although it is difficult to identify specific risk factors
that cause endothelial dysfunction within this relatively narrow cohort, diabetes, increased
small LDLp and reduced large HDLp still had significant associations, attesting to their strength
as risk factors. This unique group of patients allows us to assess the role of novel risk factors
in assessing early asymptomatic coronary atherosclerosis. The correlations that we describe
do not prove causality or provide mechanistic explanations but do support our hypothesis that
small LDLp play a role in early atherogenesis independent of LDL-C and other conventional
risk factors.
CONCLUSIONS
In a population with relatively low levels of LDL-C, NMR evaluation of lipoprotein patricles
is able to discriminate potential atherosclerotic risk better than conventional risk factors. Future
studies are needed to consolidate a compelling case for routine measurement of lipoprotein
particles and entice physicians in their quest for greater efficacy in cardiovascular risk
assessment.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The maximal change in coronary artery diameter (CAD) in response to intracoronary
acetylcholine decreased with increasing concentrations of total small LDL particles. Tertile
1: LDL particle concentration < 504.1 nmol/L; tertile 2: 504.1–865 nmol/L; tertile 3: ≥ 865
nmol/L.
*Values displayed as mean ± standard error of the mean
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Figure 2.
The maximal change in coronary artery diameter (CAD) in response intracoronary
acetylcholine increased with increasing concentrations of large HDL particles. Tertile 1: HDL
particle concentration < 4.1 μmol/L; tertile 2: 4.1 to 7.7 μmol/L; tertile 3: ≥7.7 μmol/L.
*Values displayed as mean ± standard error of the mean
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Table 1
Baseline characteristics
Variable Normal (n =179) Endothelial Dysfunction (n= 273) p
Age 49.0 ±11.5 50.6 ±11.7 0.14
Male gender 52 (29.1) 104 (38.1) 0.05
Postmenopausal female 75 (41.9) 109 (40.0) 0.90
Body mass index, kg/m2 28.0 ± 6.1 29.7 ± 6.2 0.001
Diabetes mellitus 6 (3.4) 30 (11.0) 0.002
Glycosylated hemoglobin, % 5.2 ± 0.5 5.5 ± 1.0 <0.001
hs-crp (mg/L) 0.8 ± 1.5 1.4 ± 3.3 0.14
Hyperlipidemia 92 (51.4) 158 (57.9) 0.40
Lipid Lowering agent use 53 (29.6) 104 (38.2) 0.06
Hypertension 74 (41.3) 123 (45.1) 0.72
Antihypertensive use 42 (23.5) 79 (28.9) 0.30
ACE inhibitor use 31 (17.3) 45 (16.5) 0.80
Current smokers 21 (11.7) 40 (14.7) 0.40
*
Values expressed as mean ± standard deviation or n (%)
†
ACE angiotensin converting enzyme
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Table 2
Distribution of lipids and lipoprotein particles by coronary endothelial function.
Lipid fraction Normal n = 179 Coronary Endothelial Dysfunction n = 273 p
Total cholesterol (mg/dl) 188 ± 44 191 ± 44 0.57
LDL-C (mg/dl) 106 ± 33 112 ± 38 0.24
HDL-C (mg/dl) 55 ± 18 51 ± 15 0.02
Triglycerides (mg/dl) 127 ± 76 146 ± 96 0.05
Lipoprotein (a) (mg/dl) 3.5 ± 7.3 2.5 ± 5.5 0.20
Total LDLp (nmol/L) 1078 ± 390 1158 ± 393 0.03
Mean LDLp size (nm) 20.7 20.9 0.03
Total Small LDLp (nmol/L) 687 ± 431 791 ± 434 <0.01
Large LDLp (nmol/L) 353 ± 198 324 ± 193 0.09
IDLp (nmol/L) 37 ± 40 44 ± 42 0.04
Total HDLp (μmol/L) 29.5 ± 6.8 29.0 ± 6.5 0.45
Large HDLp (μmol/L) 6.6 ± 3.7 5.7 ± 3.7 <0.01
*
Values expressed as mean ± SD
†
Endothelial dysfunction was defined as either epicardial or microvascular dysfunction or both.
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Table 3
Hemodynamic Data
Hemodynamic data Normal n = 273 Coronary Endothelial Dysfunction n = 179 p
Mean arterial pressure, mmHg 100± 15 100 ±16 0.50
Heart rate, bpm 72 ±13 70 ± 13 0.07
CFR to adenosine 3.0 ± 0.7 3.0 ± 0.7 0.20
Baseline coronary artery diameter, mm 2.3 ± 0.6 2.2 ± 0.6 0.04
Baseline CBF, ml/min 54.6 ± 35 50.8±30 0.50
% change in coronary artery diameter to acetylcholine −5.3 ± 16 −22.8 ± 24 <0.001
% change in CBF to acetylcholine 111.7 ± 101 26.1 ± 83 <0.001
*
Values expressed as mean ± SEM.
CFR: coronary flow reserve, CBF: coronary blood flow
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